MoonLake Immunotherapeutics(US:MLTX) Globenewswire·2025-10-27 14:15Core Viewpoint - A securities fraud class action lawsuit has been initiated against MoonLake Immunotherapeutics, alleging misrepresentations regarding its drug candidate sonelokimab [3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [3]. Group 2: Company Information - MoonLake's sole drug candidate, sonelokimab, was promoted as superior to competing monoclonal antibody drugs, which is central to the allegations in the lawsuit [4]. - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, which allows them to represent the class in the litigation [5]. Group 3: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless there is a recovery [5][6]. - The firm has a history of recovering over $3.5 billion for clients and has been recognized multiple times for its litigation success [6].